Gordon Dyal & Co. Advisory Group LP

Investment Banking

New York, New York 3,287 followers

Gordon Dyal & Co. Advisory Group LP provides its clients with independent advisory services on M&A transactions.

Discover all 28 employees

About us

Gordon Dyal & Co. Advisory Group LP provides its clients with independent advisory services on merger and acquisition transactions as well as special situations. The firm's core principles are integrity, discretion, loyalty, and execution excellence. Broker Dealer Services are provided by Gordon Dyal & Co., LLC Gordon E. Dyal founded the firm to build long-term strategic client relationships across multiple industries worldwide. Gordon Dyal & Co. Advisory Group LP distinguishes its client service through judgment, candor, and the team's cumulative investment banking experience.

Website: http://www.gordondyalco.com
External link for Gordon Dyal & Co. Advisory Group LP
Industry: Investment Banking
Company size: 11-50 employees
Headquarters: New York, New York
Type: Partnership
Founded: 2016
Specialties: Mergers & Acquisitions Advisory, Investment Banking, and Anti-Raid Advisory

Locations

Primary

152 West 57th Street

25th Floor

New York, New York 10019, US

Get directions

Employees at Gordon Dyal & Co. Advisory Group LP

See all employees

Updates

Gordon Dyal & Co. Advisory Group LP

3,287 followers
1mo
Report this post
Congratulations to the Dewpoint team on their license agreement with Bayer. Gordon Dyal & Co., LLC is delighted to have acted as the exclusive financial advisor to Dewpoint Therapeutics in this transaction.

Dewpoint Therapeutics

11,722 followers
1mo

📢 We are thrilled to announce a significant milestone in the Dewpoint - Bayer AG collaboration: licensing of the first condensate modulating asset (#cmod) by Bayer, to be developed into a therapy to help patients suffering from genetically defined dilated cardiomyopathy. Read more here: https://lnkd.in/dTfiKWGG

Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program | Dewpoint Therapeutics

https://dewpointx.com

Like Comment Share
Gordon Dyal & Co. Advisory Group LP

3,287 followers
1mo
Report this post
Rio Tinto has just announced the acquisition of Arcadium Lithium, in an all-cash transaction valued at $6.7bn. Arcadium shareholders will receive $5.85 per share, a 109% premium to the unaffected share price prior to media speculation about the deal. The transaction is anticipated to close in Q2 2025, subject to an Arcadium shareholder vote. Gordon Dyal & Co. LLC served as lead financial advisor to Arcadium and UBS also advised Arcadium on the transaction. https://lnkd.in/eMzwVbV3

Rio-Tinto-to-acquire-Arcadium-Lithium-October-9-2024.pdf

s203.q4cdn.com

1 Comment

Like Comment Share
Gordon Dyal & Co. Advisory Group LP

3,287 followers
2mo
Report this post
Gordon Dyal & Co., LLC is acting as the lead financial advisor to AngloGold Ashanti in the acquisition of Centamin for stock and cash in a transaction valued at $2.5bn at announcement.
AngloGold Ashanti

413,228 followers
2mo

AngloGold Ashanti plc and Centamin plc have announced that they have reached an agreement on the terms of a recommended acquisition of Centamin. Learn more at: https://lnkd.in/dXykb8-z
Like Comment Share
Gordon Dyal & Co. Advisory Group LP

3,287 followers
2mo
Report this post
Gordon Dyal & Co., LLC is acting as the lead financial advisor to AngloGold Ashanti in the acquisition of Centamin for stock and cash in a transaction valued at $2.5bn at announcement. https://lnkd.in/ezxdPP9B

Like Comment Share
Gordon Dyal & Co. Advisory Group LP

3,287 followers
11mo
Report this post
Gordon Dyal & Co LLC advised Bristol Myers Squibb on the acquisition of Karuna Therapeutics for a total equity value of $14.0 billion. https://lnkd.in/eUGxcuzZ

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics

news.bms.com

Like Comment Share

Gordon Dyal & Co. Advisory Group LP

Investment Banking

New York, New York 3,287 followers

Gordon Dyal & Co. Advisory Group LP provides its clients with independent advisory services on M&A transactions.

About us

Locations

Employees at Gordon Dyal & Co. Advisory Group LP

Stefan Grimbacher

Managing Director, Investment Banking | M&A @ Gordon Dyal & Co.

Patrick Orzel

Managing Director and Chief Operating Officer at Gordon Dyal & Co.

Kevin Xu

Vice President, Investment Banking at Gordon Dyal & Co. Advisory Group LP

Tom Velanovich

Vice President at Gordon Dyal & Co. Advisory Group LP

Updates

Join now to see what you are missing

Similar pages

M. Klein & Company

Ducera Partners LLC

Robey Warshaw

Ardea Partners

LionTree

Allen & Company LLC.

Perella Weinberg

Centerview Partners

Zaoui & Co.

Evercore

Browse jobs

Investment Banking Analyst jobs

Intern jobs

Analyst jobs

Investment Banking Associate jobs

Program Assistant jobs

Global Head jobs

Finance Intern jobs

Associate jobs

Fund Accountant jobs

Energy Analyst jobs

Quantitative Analyst jobs

Real Estate Associate jobs

Private Equity Associate jobs

Summer Intern jobs

Investment Analyst jobs

Pricing Specialist jobs

Private Equity Intern jobs

Trading Assistant jobs

Corporate Development Specialist jobs

Chief Technology Officer jobs